Successful Treatment of MuSK Antibody-Positive Myasthenia Gravis with Rituximab
JOURNAL OF CHILD - COCUK DERGISI, vol.25, no.3, pp.172-175, 2025 (ESCI, TRDizin)
- Publication Type: Article / Article
- Volume: 25 Issue: 3
- Publication Date: 2025
- Doi Number: 10.26650/jchild.2025.1704940
- Journal Name: JOURNAL OF CHILD - COCUK DERGISI
- Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
- Page Numbers: pp.172-175
- Eskisehir Osmangazi University Affiliated: Yes
Abstract
Muscle-specific tyrosine kinase antibody-associated myasthenia gravis (MuSK-MG) is a rare subtype of MG distinguished by recurring relapses and a clinical history unresponsive to conventional therapies. Rituximab, a monoclonal antibody that targets CD20+ B cells, has effectively induced long-term remission in adults. We report a pediatric MuSK-MG patient who exhibited a favourable response to rituximab following the ineffectiveness of steroid therapy and acetylcholinesterase inhibitor (AChEI) therapy.